AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32672795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for BRAF V600E/K-mutant melanoma without prior BRAFi (n=163)
Number of subjects: 1558
Study 34473607 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 1918
Study 33236461 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 191218
Study 33236461 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 191218
Study 33236461 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 191218
Study 37080863 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light exposure and morning light avoidance
Number of subjects: 57
Study 37080863 — intervention group
Group type: COMPARATOR
Intervention: Diet modification (control intervention)
Number of subjects: 57
Study 37080863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 57
Study 32694032 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB + iPACK block and continuous ACB (CACB)
Number of subjects: 76
Study 32694032 — intervention group
Group type: COMPARATOR
Intervention: ACB + PAI and continuous ACB (CACB)
Number of subjects: 76
Study 33595208 — intervention group
Group type: EXPERIMENTAL
Intervention: letter-to-future condition
Number of subjects: 738
Study 33595208 — intervention group
Group type: EXPERIMENTAL
Intervention: letter-from-future condition
Number of subjects: 738
Study 33595208 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 738
Study 33045195 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 100
Study 33045195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 35653917 — intervention group
Group type: COMPARATOR
Intervention: POL group (produced in-lab with a polished surface)
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM group
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM Bur group
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: DBO group
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: DBXY group
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: SiC group (#60-grit silicon carbide sandpaper)
Number of subjects: 15
Study 35653917 — intervention group
Group type: EXPERIMENTAL
Intervention: WS group (#60-grit wood sandpaper)
Number of subjects: 15
Study 33926921 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017 (Hyrimoz)
Number of subjects: 1318
Study 33926921 — intervention group
Group type: COMPARATOR
Intervention: SB5 (Imraldi)
Number of subjects: 1318
Study 32340375 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily water intake (two additional 550 mL bottles of water consumed daily)
Number of subjects: 55
Study 33471487 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE+TUDCA treatment for 8 weeks
Number of subjects: 63
Study 33471487 — intervention group
Group type: COMPARATOR
Intervention: Sham ACE+TUDCA treatment for 8 weeks
Number of subjects: 63
Study 34867786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 182
Study 34867786 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet plus placebo injections
Number of subjects: 182
Study 34867786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide responder group
Number of subjects: 182
Study 32100652 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 760
Study 34265218 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation including nutritional supplements (fish oil with vitamin D3 + whey protein with leucine), exercise and relaxation
Number of subjects: 34
Study 34265218 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 34
Study 32683400 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐dependent Diabetes Mellitus (IDDM)
Number of subjects: 305
Study 32683400 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive GAD65 antibodies
Number of subjects: 305
Study 35739553 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation for Minimizing the Duration of MV (PROMIZING) study algorithm
Number of subjects: 374
Study 32297918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline objective visual impairment (visual acuity worse than 20/40, 20/80, or 20/100)
Number of subjects: 1061
Study 32297918 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline objective visual impairment
Number of subjects: 1061
Study 32297918 — intervention group
Group type: COMPARATOR
Intervention: No baseline visual impairment
Number of subjects: 1061
Study 35688358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimitespib 160 mg/day
Number of subjects: 86
Study 35688358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 35688358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimitespib (cross-over adjusted)
Number of subjects: 86
Study 35688358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after cross-over)
Number of subjects: 86
Study 35688358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimitespib
Number of subjects: 86
Study 34542212 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Curtain
Number of subjects: 9
Study 34542212 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual activities
Number of subjects: 9
Study 36311293 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine combined with ultrasound-guided pectoral nerve block type II (Pecs II block)
Number of subjects: 136
Study 36311293 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil for anesthesia induction and PCIA
Number of subjects: 136
Study 34491652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton-moxibustion, applied once a day, 3 cones at a time for 3 weeks
Number of subjects: 66
Study 34491652 — intervention group
Group type: COMPARATOR
Intervention: Compound flumetasone ointment, applied twice a day for 3 weeks
Number of subjects: 66
Study 36220355 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component EHR-based intervention
Number of subjects: 10000
Study 36220355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10000
Study 34389519 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 528
Study 34389519 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 528
Study 34389519 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT
Number of subjects: 528
Study 34018445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% cream
Number of subjects: 44
Study 34018445 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 44
Study 32614394 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) with heavy external loading (90% of one repetition maximum)
Number of subjects: 36
Study 32614394 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded ballistic training (UBT) without heavy external loading
Number of subjects: 36
Study 32614394 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 32614394 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 36
Study 35329815 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Nitrous Oxide-Oxygen (50%N2 O‐O2)
Number of subjects: 88
Study 35329815 — intervention group
Group type: COMPARATOR
Intervention: Medical Air (Control)
Number of subjects: 88
Study 32247073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 149
Study 32247073 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 149
Study 35922271 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery meditation
Number of subjects: 68
Study 35922271 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 35894916 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral home-based strength training (3 sets of 12 repetitions of progressively loaded unilateral calf raises, 3 days per week)
Number of subjects: 34
Study 35894916 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral home-based strength training
Number of subjects: 34
Study 35894916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 33421039 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (1.5 hours of integrated yoga practice every other day for 1 month)
Number of subjects: 53
Study 33421039 — intervention group
Group type: COMPARATOR
Intervention: Control group (group discussion session twice a week for 1 month)
Number of subjects: 53
Study 33421039 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison of post-intervention scores
Number of subjects: 53
Study 32410200 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (low‐level laser therapy) including red light (660 nm), infrared light (840 nm), and infrared laser applied on the first postoperative day
Number of subjects: 60
Study 33890319 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 106
Study 33890319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 34674688 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-text messaging intervention (4 messages per week)
Number of subjects: 1186
Study 34674688 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1186
Study 35122442 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using a diode laser, 808 nm, 250 mW; 16.25 J; 32.5 J cm-2
Number of subjects: 30
Study 35122442 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic gel (Benzocaine 20%)
Number of subjects: 30
Study 33905482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia at 44ºC
Number of subjects: 53
Study 33905482 — intervention group
Group type: COMPARATOR
Intervention: Control (37ºC)
Number of subjects: 53
Study 35270420 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Package Program plus routine care (n = 98)
Number of subjects: 196
Study 35270420 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (n = 98)
Number of subjects: 196
Study 34754346 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% 15 ml plus ketamine 0.5 mg/kg (LK group)
Number of subjects: 50
Study 34754346 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% 15 ml plus 5 ml normal saline (L group)
Number of subjects: 50
Study 33908182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethandrolone undecanoate (DMAU)
Number of subjects: 0
Study 33908182 — intervention group
Group type: EXPERIMENTAL
Intervention: 11β-Methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC)
Number of subjects: 0
Study 33908182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34233331 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCEPT® (Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment) for 3 months with standard oncological care (SOC)
Number of subjects: 20
Study 34233331 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group receiving standard oncological care (SOC) only for 3 months
Number of subjects: 20
Study 36331570 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated strategy of renal-replacement therapy (RRT) initiation
Number of subjects: 1121
Study 36331570 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy of renal-replacement therapy (RRT) initiation
Number of subjects: 1121
Study 36331570 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 1121
Study 36331570 — intervention group
Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 1121
Study 34806624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided botulinum toxin injection (50 units of botulinum toxin type A)
Number of subjects: 40
Study 34806624 — intervention group
Group type: COMPARATOR
Intervention: Balloon catheter dilatation therapy (five times per week for two weeks)
Number of subjects: 40
Study 35568336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in 1 randomly selected eye
Number of subjects: 889
Study 35568336 — intervention group
Group type: COMPARATOR
Intervention: Untreated control eyes
Number of subjects: 889
Study 32034202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (5 mg) by mesh nebulization
Number of subjects: 12
Study 32034202 — intervention group
Group type: COMPARATOR
Intervention: Inhaled milrinone (5 mg) by jet nebulization
Number of subjects: 12
Study 33203426 — intervention group
Group type: EXPERIMENTAL
Intervention: early palliative radiation
Number of subjects: 74
Study 33203426 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 74
Study 35739713 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purification treatment
Number of subjects: 24
Study 35739713 — intervention group
Group type: COMPARATOR
Intervention: Sham air purification treatment
Number of subjects: 24
Study 35739713 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (outdoor, indoor, and time-weighted personal)
Number of subjects: 24
Study 33493624 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated iTBS
Number of subjects: 37
Study 33493624 — intervention group
Group type: COMPARATOR
Intervention: Non-neuronavigated F3 guided iTBS
Number of subjects: 37
Study 33493624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 35645072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescence with Lugol's iodine
Number of subjects: 84
Study 35645072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescence with toluidine blue
Number of subjects: 84
Study 33037810 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate 50 mg daily plus conventional hospital management
Number of subjects: 49
Study 33037810 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital management
Number of subjects: 49
Study 36251731 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive training
Number of subjects: 0
Study 36251731 — intervention group
Group type: COMPARATOR
Intervention: Randomly interleaved training
Number of subjects: 0
Study 32404731 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (2011-2013)
Number of subjects: 1998
Study 32404731 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (2014)
Number of subjects: 1998
Study 32404731 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 1998
Study 34131850 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Riding (THR)
Number of subjects: 27
Study 34131850 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMath (HM)
Number of subjects: 27
Study 34131850 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 35288291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 36
Study 35288291 — intervention group
Group type: COMPARATOR
Intervention: Localized DVT (Control)
Number of subjects: 36
Study 32429720 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative inosine pranobex immunotherapy
Number of subjects: 32
Study 32429720 — intervention group
Group type: COMPARATOR
Intervention: No postoperative immunotherapy
Number of subjects: 32
Study 36207508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of lixisenatide and basal insulin (BI)
Number of subjects: 2679
Study 36207508 — intervention group
Group type: COMPARATOR
Intervention: Sequential initiation of lixisenatide and basal insulin (BI)
Number of subjects: 2679
Study 33744902 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular prismatic double-J (DJ) stent
Number of subjects: 152
Study 33744902 — intervention group
Group type: COMPARATOR
Intervention: Standard DJ stent
Number of subjects: 152
Study 32325856 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan (YBG) 250 mg/day
Number of subjects: 31
Study 32325856 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLA)
Number of subjects: 31
Study 36126213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler Restylane Defyne
Number of subjects: 140
Study 36126213 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 140
Study 32862111 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN β‐1b (250 mcg subcutaneously every other day for two consecutive weeks)
Number of subjects: 80
Study 32862111 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN β‐1b
Number of subjects: 80
Study 32862111 — intervention group
Group type: COMPARATOR
Intervention: Control group (national protocol medications: lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7–10 days)
Number of subjects: 80
Study 33541794 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB
Number of subjects: 5200
Study 33541794 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 5200
Study 35123553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1
Number of subjects: 180
Study 35123553 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel (GnP)
Number of subjects: 180
Study 32182798 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance, organization support, and eudaimonia
Number of subjects: 116
Study 32182798 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance, organization support, and purpose
Number of subjects: 116
Study 32182798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower endurance
Number of subjects: 116
Study 34400438 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 30
Study 34400438 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal band ligation
Number of subjects: 30
Study 33074739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dislocation group (50 patients)
Number of subjects: 707
Study 33074739 — intervention group
Group type: COMPARATOR
Intervention: No dislocation group (94 patients)
Number of subjects: 707
Study 34927213 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous orthodontic force of 150 g applied for 8 weeks, reactivated after 28 days.
Number of subjects: 8
Study 34927213 — intervention group
Group type: COMPARATOR
Intervention: Intermittent orthodontic force (21 days on, 7 days off) of 150 g applied for 8 weeks.
Number of subjects: 8
Study 35384391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) capsules, administered 5 times over 3 weeks
Number of subjects: 10
Study 35384391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) capsules
Number of subjects: 10
Study 33234419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet orange inhalation
Number of subjects: 120
Study 33234419 — intervention group
Group type: EXPERIMENTAL
Intervention: Damask rose inhalation
Number of subjects: 120
Study 33234419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 120
Study 616120115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (Group 1: well controlled DM, HbA1c ≤7%)
Number of subjects: 50
Study 616120115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (Group 2: poorly controlled DM, HbA1c >7%)
Number of subjects: 50
Study 616120115 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study 35142713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1561 ± 470 g·d‐1)
Number of subjects: 14
Study 35142713 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training + Placebo (RT + PLAC)
Number of subjects: 14
Study 35142713 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training + Metformin (RT + MET)
Number of subjects: 14
Study 35142713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 14
Study 34516683 — intervention group
Group type: EXPERIMENTAL
Intervention: Marte Meo and Coordination Meetings (MAC)
Number of subjects: 99
Study 34516683 — intervention group
Group type: COMPARATOR
Intervention: Service as Usual (SAU)
Number of subjects: 99
Study 35561644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline food insecurity
Number of subjects: 0
Study 35561644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline utilities insecurity
Number of subjects: 0
Study 35561644 — intervention group
Group type: EXPERIMENTAL
Intervention: Child or family care responsibilities at baseline
Number of subjects: 0
Study 34755012 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 1025
Study 34755012 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1025
Study 32083594 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin contact (SSC)
Number of subjects: 47
Study 32083594 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (radiant warmer with continuous pulse oximeter monitoring)
Number of subjects: 47
Study 33371122 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine
Number of subjects: 48
Study 33371122 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 48
Study 35992542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational lateral femoral vascular inlay broad fascial flap repair
Number of subjects: 32
Study 35992542 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin flap repair
Number of subjects: 32
Study 34422259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin (vitamin B12) supplementation
Number of subjects: 561
Study 34422259 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 561
Study 34422259 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic status and dietary characteristics
Number of subjects: 561